Sarepta Therapeutics ( SRPT ) shares were down 50% in recent pre market trade, extending Thursday’s declines in the wake of the U.S. Food and Drug Administration’s rejection of rival BioMarin Pharmaceutical’s ( BMRN ) new drug application for
Sarepta Therapeutics Plummets 50% as FDA Rejects BioMarin's NDA For Duchenne Muscular Dystrophy
